OMCL Stock — Omnicell, Inc.

Omnicell, Inc. (OMCL)

Updated October 16, 2026.

OMCL is a Stock. Total return is 272.1% over the past 25.2 years, 623.0 points behind SPY at 895.1%.

Omnicell, Inc. develops healthcare technology solutions for hospitals, health systems, and pharmacies, including automated medication dispensing systems, IV compounding equipment, specialty pharmacy services, and digital platforms for medication management and traceability. The company does not currently distribute dividends to shareholders. Omnicell is oriented toward growth-focused investors seeking exposure to healthcare automation and medication management technology rather than income generation.

OMCL performance versus SPY

Price and return data through 2026-10-16.

Total return is 272.1% over the past 25.2 years, 623.0 points behind SPY at 895.1%. Over the past year its total return — price change plus distributions reinvested — is 16.8%. Its deepest 1-year drawdown was 37.3%.

OMCL key facts

Asset type

Stock

Asset class

Equity

Inception date

08/07/2001

Distribution frequency

None

Last close

$35.39 (as of 2026-10-16)

Market cap

$1,614,310,745

Average volume

426646.0

Beta

0.986

Payout ratio

0.0%

P/E ratio

42.13

Forward P/E

29.4985

EPS

$0.84

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OMCL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 37.3%.

Who may consider OMCL — and who may not

It is a weaker fit for investors who need monthly cash flow (OMCL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OMCL

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions